meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced mGC or mGEJC
mGC or mGEJC - 1st line (L1)
mGC or mGEJC - L1 - all population
mGC or mGEJC - L1 - HER2 neg/PDL1 positive
2
mGC or mGEJC - L1 - HER2 negative
1
mGC or mGEJC - L1 - HER2 positive
mGC or mGEJC - L1 - PDL1 positive
4
mGC or mGEJC - 2nd Line (L2)
mGC or mGEJC - L2 - all population
4
mGC or mGEJC - L2 - PDL1 positive
1
mGC or mGEJC - maintenance (M)
mGC or mGEJC - M - HER2 negative
1
mGC or mGEJC - M - HER2 neg/PDL1 positive
1
gene alteration defined cancer
immune chekpoint inhibitors
anti-PD-(L)1
nivolumab based treatment
nivolumab plus SoC
versus all
vs chemotherapy
vs Standard of Care (SoC)
All patients
Age < 65y (younger)
Age > 65y
Asian type
cancer location (esophagus)
cancer location (gastric)
cancer location (gastro-esophageal)
ECOG 0
ECOG 1
Gender, female
Gender, male
metastasis (liver )
PD-L1 < 1%
PD-L1 > 1%
previous gastrectomy
previous gastrectomy NO
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
deaths (OS)
mGC or mGEJC - L1 - HER2 neg/PDL1 positive
metastatic/advanced mGC or mGEJC
mGC or mGEJC - 1st line (L1)
mGC or mGEJC - L1 - HER2 neg/PDL1 positive
versus Standard of Care (SoC)
nivolumab plus SoC vs. Standard of Care (SoC)
2
certainty unassessable
statistically conclusive
-27%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open